crossing the
Barrier

NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). Using NeOnc’s formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provide patients with potentially more effective treatments.
the
Problem
The potential for greater success in treating CNS-based diseases such as Glioblastoma remains limited by the inability to deliver therapeutics directly to the brain.
READ MORE >
our
Solution
Our proprietary approaches and patented technologies deliver new therapies for treating brain cancers as well as facilitating the transport of established or new therapeutics across the blood-brain barrier to improve efficacy for the treatment of diseases in the brain.
READ MORE >
the
Potential
By providing a regulator for tumor cell growth along with a transport mechanism for therapeutics, plan to provide doctors and health-care professionals with a way to deliver better outcomes for their patients.
READ MORE >
LATEST RESEARCH and STUDY
NeOnc maintains an aggressive regimen of research and study into its delivery of therapeutics and formulations to validate and ensure our ability to have an impact on the treatment of CNS-based disease.
NEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma
NEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.
Study Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damage
NEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells
Transfemoral Injection of NEO100 Provides Potential for Delivery of Therapeutics to the Brain
Postsurgical Biopsy Shows Viability of NEO100 Intranasal Delivery
NEO-212 Shows Promise In Treating Acute Myeloid Leukemia
NEO100 Enhances Delivery Of Herceptin For Treatment Of Metastatic Breast Cancer In The Brain
NEO100 Human Trial In Adult Patients With Recurrent Glioblastoma
Understanding The Pharmacokinetic Properties Of NEO 212
Study Supporting NEO100’s Ability To Deliver Through The BBB
Improving Therapeutic Efficacy For Brain-Based Cancers Using NEO100
NEO 212 Enhances Temozolomide’s Ability To Increase Radiosensitivity And Cytotoxicity In Glioblastoma Tumors
Intranasal Delivery Of BZM With NEO 100 Prolonged Survival Of Glioblastoma Tumors In Animals
NEO214 Shown To Be A Mediator Of Cell Death In Patients With TMZ-Resistant GBM
POH Shows Ability To Bypass The Blood Brain Barrier For Intranasal Delivery Of Therapeutics
TMZ-POH Shows Positive Effect On Patients With Nasopharyngeal Carcinoma.
NEO212 Shows Ability To Help Block Pro-Angiogenic And Invasive Characteristics Of GBM
Further NEO 212 Studies Shows Ability To Slow GBM Cell Invasion at Sub-Cytotoxic Dose
NEO100 Enables Noninvasive, Effective Delivery of Therapeutics
NEO214 Effectively Kills Multiple Myeloma Cells With An Order Of Magnitude Stronger Than Its Individual Components
Initial Study Shows The Cytotoxic Effects Of Intranasal Delivered POH
PRESS RELEASES
The following are the latest Press Releases and Announcements regarding NeOnc Technologies Holdings’ advancements. To see all the Press Releases, click HERE
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
NeOnc Expects Full Enrollment In Phase 2a Trial of NEO100-01
NeOnc Executive Chairman Assumes Expanded Leadership Role
NeOnc Nears Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100
NeOnc Technologies Partners with CBCC Global Research for Clinical Trials on NEO100-01
NeOnc Technologies Holdings Announces SEC S-1 Registration For Anticipated On NASDAQ
NeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
NeOnc Technologies Appointments the Honorable Dr. Steven L. Giannotta to its Board of Directors
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
NeOnc Technologies Holdings, Inc. Appoints Dr. Alan Chiang to Board of Directors
NeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
USA Today Puts The Spotlight On NeOnc’s Dr. Thomas Chen.
NeOnc Begins Enrollment for Phase 2 Clinical Trial of NEO100-02
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212
LA Weekly Puts The Spotlight On NeOnc Technologies Holdings, Inc. Non-Invasive Drug Delivery Platform
NeOnc Technologies Completes $18.5 Million Financing
NeOnc Receives Breakthrough Medical Technology Achievement Award from CIS
NeOnc Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board
NeOnc’s CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
NeOnc Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
NEO212 Inhibits Migration And Invasion Of Glioma Stem Cells
IN THE NEWS
News about NeOnc’s technology platform continues to expand. Following are some of the articles that have been written about our progress.